SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through... Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.
- Mechanism
- Curator reviewed
SC12267, a novel, selective and orally available, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), interferes with cell proliferation through blocking the synthesis pathway of pyrimidines. Its mode-of- action is of therapeutic relevance for the treatment of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.
- Primary indication
- Investigated for use/treatment in multiple sclerosis and rheumatoid arthritis.Curator reviewed
- Code names
- SC12267
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with SC12267, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account